Crohn's Disease News and Research RSS Feed - Crohn's Disease News and Research

Crohn’s disease is a chronic inflammatory disease of the bowel affecting at least 115,000 people in the UK. The condition usually develops in teenagers and young adults, but can be diagnosed at any age and is equally common in men and women.

The condition can affect any part of the digestive tract between the mouth and the anus, although inflammation in the last section of the small bowel (ileum) or the first part of the large bowel (colon) is most common.

Crohn's disease is a ‘relapsing and remitting’ condition characterized by symptom-free periods followed by episodes of “flare-ups,” during which symptoms such as diarrhoea, abdominal pain, fever and fatigue may become particularly bothersome.

Long term, severe inflammation can damage sections of the digestive system, resulting in additional complications, such as a tear in the wall of the anus (fissure), narrowing of the intestine (stricture) or the formation of an abnormal connection between the bowel and another body part such as the bladder, vagina or skin (fistula). Such problems usually require surgical treatment to correct. Crohn's disease also increases the risk of developing bowel cancer.

The exact cause of Crohn's disease is not clear but experts believe a combination of factors may be at work including genetics, immune responses to certain bacteria or viruses and lifestyle factors such as diet or smoking status.
Unique bacterial biomarkers may help develop diagnostics, treatments for liver cirrhosis

Unique bacterial biomarkers may help develop diagnostics, treatments for liver cirrhosis

ENTEROME Bioscience SA, a pioneer in the development of innovative disease management solutions based on a deep understanding of the gut microbiome, and with a strong focus on liver diseases, highlights the advanced online publication in Nature of a research paper describing the identification of a unique series of bacterial biomarkers that could provide new opportunities for the development of diagnostics and treatments for liver cirrhosis. [More]
Lyfebulb, Immune collaborate to increase awareness of bullous pemphigoid

Lyfebulb, Immune collaborate to increase awareness of bullous pemphigoid

Lyfebulb, the International Pemphigus Pemphigoid Foundation (IPPF) and Immune Pharmaceuticals Inc., announced a collaboration to increase awareness of unmet needs in treating bullous pemphigoid last night at an event attended by more than sixty patients, physicians, scientists and other interested parties. [More]

Showers and rivers may play role in the development of Crohn's disease

Humans may be exposed to bacteria linked with Crohn's disease through fine spray from showers and rivers according to research led by Lancaster University. [More]
People who grow up farm with livestock better protected against inflammatory bowel diseases

People who grow up farm with livestock better protected against inflammatory bowel diseases

New research conducted at Aarhus University has revealed that people who have grown up on a farm with livestock are only half as likely as their urban counterparts to develop the most common inflammatory bowel diseases: ulcerative colitis and Crohn's disease. [More]
Researchers identify new genes that likely contribute to asthma

Researchers identify new genes that likely contribute to asthma

In a study published yesterday in the scientific journal Nature Immunology, a group at the La Jolla Institute (LJI) led by Pandurangan Vijayanand, Ph.D. identify new genes that likely contribute to asthma, a disease that currently affects over 200 million people world wide. [More]
Researchers develop new "nanojuice" to help doctors better identify human gut

Researchers develop new "nanojuice" to help doctors better identify human gut

Located deep in the human gut, the small intestine is not easy to examine. X-rays, MRIs and ultrasound images provide snapshots but each suffers limitations. Help is on the way. [More]
Treating ulcerative colitis and Crohn’s disease: an interview with Dr. Stephen Hanauer, Medical Director, Digestive Health Center, Northwestern University Feinberg School of Medicine

Treating ulcerative colitis and Crohn’s disease: an interview with Dr. Stephen Hanauer, Medical Director, Digestive Health Center, Northwestern University Feinberg School of Medicine

Ulcerative colitis and Crohn’s disease are idiopathic (we don’t know the cause) inflammatory diseases (IBD) of the colon and/or small bowel. They are chronic in that we do not have a medical cure and are differentiated from IBS (irritable bowel syndrome) by inflammation that causes ulcerations of the GI tract. [More]
Research on intestinal microbiota overturns vision of human gut ecosystem

Research on intestinal microbiota overturns vision of human gut ecosystem

An international research team within the MetaHIT consortium coordinated by INRA and involving teams from CEA, CNRS and Université d'Evry, has developed a new method to analyse the global genome, or the metagenome of the intestinal microbiota. [More]
UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, a global biopharmaceutical leader, and Dermira, Inc., a privately held US-based dermatology company, announced today that they have entered into an exclusive licensing agreement for the development and future commercialization of Cimzia (certolizumab pegol) in dermatology. [More]
Alaska to be hit hard with hospital infection penalties

Alaska to be hit hard with hospital infection penalties

Elsewhere, medical marijuana's usefulness in treating pain is questioned after New York lawmakers legalized it. [More]
First Edition: June 27, 2014

First Edition: June 27, 2014

Today's early morning highlights from the major news organizations, including reports on an HHS announcement detailing some of the marketplace enrollment plans for next fall. [More]
Microparticles in crab, shrimp and lobster shells may help prevent inflammatory bowel disease

Microparticles in crab, shrimp and lobster shells may help prevent inflammatory bowel disease

Yoshimi Shibata, Ph.D., professor of biomedical science in the Charles E. Schmidt College of Medicine at Florida Atlantic University, has received a $380,552 grant from the National Institute of Complementary and Alternative Medicine of the National Institutes of Health to further investigate how microparticles called "chitin" found in crab, shrimp and lobster shells have anti-inflammatory mechanisms that could lead to the development of novel preventive and therapeutic strategies for individuals who suffer from inflammatory bowel disease (IBD) and others diseases. [More]
New research reveals gene's role in type 1 diabetes

New research reveals gene's role in type 1 diabetes

New research describes details of how a diabetes-related gene functions on a biological pathway that affects the release of insulin. The study authors say that finding drugs that act on that pathway may eventually lead to a new treatment for type 1 diabetes. [More]
La Jolla Institute researchers advance work toward vaccine for heart disease

La Jolla Institute researchers advance work toward vaccine for heart disease

Research toward the world's first vaccine for heart disease continues to advance at the La Jolla Institute for Allergy and Immunology, with researchers demonstrating significant arterial plaque reduction in concept testing in mice. [More]
Tumor necrosis factor alpha antagonists not linked with increased risk of cancer

Tumor necrosis factor alpha antagonists not linked with increased risk of cancer

In a study that included more than 56,000 patients with inflammatory bowel disease, use of a popular class of medications known as tumor necrosis factor alpha antagonists was not associated with an increased risk of cancer over a median follow-up of 3.7 years, although an increased risk of malignancy in the long term, or with increasing number of doses, cannot be excluded, according to a study in the June 18 issue of JAMA. [More]
AbbVie's ALIGN study underscores patients’ attitudes and adherence toward TNF inhibitors

AbbVie's ALIGN study underscores patients’ attitudes and adherence toward TNF inhibitors

AbbVie today announced results from its multi-country ALIGN study, which shows that across six chronic immune-mediated inflammatory diseases (IMIDs), adherence to treatment was generally higher in patients being treated with TNF inhibitors compared to patients treated with conventional therapy. [More]
Nektar reports etirinotecan pegol Phase 2 study results in patients with Avastin-refractory high-grade glioma

Nektar reports etirinotecan pegol Phase 2 study results in patients with Avastin-refractory high-grade glioma

Nektar Therapeutics announced today new data from an investigator-sponsored Phase 2 study of NKTR-102 (etirinotecan pegol) in patients with Avastin-refractory high-grade glioma conducted at Stanford Cancer Institute under the direction of Lawrence Recht, M.D., Professor of Neurology and Neurosurgery, with co-investigator Seema Nagpal, M.D., Clinical Assistant Professor of Neurology and Neurological Sciences, Stanford School of Medicine. [More]
EC approves Takeda's Entyvio for treatment of adults with ulcerative colitis, Crohn’s disease

EC approves Takeda's Entyvio for treatment of adults with ulcerative colitis, Crohn’s disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals International GmbH, today announced that the European Commission has granted Marketing Authorisation for Entyvio (vedolizumab), a gut-selective humanized monoclonal antibody, and the first and only biologic therapy to be approved simultaneously for the treatment of adults with moderately to severely active ulcerative colitis (UC) and adults with moderately to severely active Crohn’s disease (CD) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα) antagonist. [More]

Gastroenterologists select efficacy over safety, tolerability when prescribing new drug for Crohn's disease

Decision Resources Group finds that, when asked to indicate the relative importance of product attributes when prescribing a new drug for Crohn's disease (CD), the highest percentages of surveyed gastroenterologists in the United States and Europe selected efficacy over safety and tolerability or delivery. [More]
Cell Science Systems launches new blood test profile for GI disorders

Cell Science Systems launches new blood test profile for GI disorders

Distinguishing the cause of gut disorders can be complicated. Therefore, Cell Science Systems, Corp. today announced the launch of a new test to help clinicians reach a diagnosis; and, suggest dietary strategies to improve whatever gut malady a person may have. [More]